Disruptive chemicals, senescence and immortality

Carcinogenesis

Volumn 36, Issue , 2015, Pages S19-S37

  Carnero, Amancio ^s   Blanco Aparicio, Carmen ^a   Kondoh, Hiroshi ^b   Lleonart, Matilde E ^c   Martinez Leal, Juan Fernando ^d   Mondello, Chiara ^e   Scovassi, A Ivana ^e   Bisson, William H ^f   Amedei, Amedeo ^g   Roy, Rabindra ^h   Woodrick, Jordan ^h   Colacci, Annamaria ⁱ   Vaccari, Monica ⁱ   Raju, Jayadev ^j   Al Mulla, Fahd ^k   Al Temaimi, Rabeah ^k   Salem, Hosni K ^l   Memeo, Lorenzo ^m   Forte, Stefano ^m   Singh, Neetu ⁿ   Hamid, Roslida A ^o   Ryan, Elizabeth P ^p   Brown, Dustin G ^p   Wise, John Pierce ^q   Wise, Sandra S ^q   Yasaei, Hemad ^r   more..

^a Structural Biology and Biocomputing Programme   (Spain)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Cell Biology Department   (Spain)

^e CNR   (Italy)

^f OREGON STATE UNIVERSITY   (United States)

^g UNIVERSITY OF FLORENCE   (Italy)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ Center for Environmental Carcinogenesis and Risk Assessment   (Italy)

^j TOXICOLOGY RESEARCH DIVISION   (Canada)

^k KUWAIT UNIVERSITY   (Kuwait)

^l CAIRO UNIVERSITY   (Egypt)

^m Mediterranean Institute of Oncology   (Italy)

ⁿ KING GEORGE'S MEDICAL UNIVERSITY   (India)

^o UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^p Food Science and Human Nutrition   (United States)

^q UNIVERSITY OF SOUTHERN MAINE   (United States)

^r BRUNEL UNIVERSITY   (United Kingdom)

^s UNIVERSITY OF SEVILLE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CELL CYCLE PROTEIN; HYDROGEN PEROXIDE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; TELOMERASE; DANGEROUS GOODS; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DIETHYLSTILBESTROL; NICKEL CHLORIDE; PHENOBARBITAL; PROTEIN P16; RESERPINE; TRANSCRIPTION FACTOR E2F;

CANCER GROWTH; CARCINOGENESIS; CELL AGING; CELL CYCLE ARREST; CELL DISRUPTION; CELL FUNCTION; CELL IMMORTALIZATION; CELL METABOLISM; CELL POPULATION; CELL PROLIFERATION; CELL STRESS; CHEMICAL MODIFICATION; CHRONIC INFLAMMATION; CLONAL EVOLUTION; DNA BINDING; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA METHYLATION; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE CONTROL; GENE EXPRESSION; GENETIC CODE; GENETIC VARIABILITY; GENOTOXICITY; HETEROZYGOSITY LOSS; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; ONCOGENE RAS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; REVIEW; SIGNAL TRANSDUCTION; SOMATIC CELL; TELOMERE HOMEOSTASIS; TUMOR PROMOTION; ULTRAVIOLET RADIATION; UPREGULATION; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DANGEROUS GOODS; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; CELL CLONE; INFLAMMATION; SENESCENCE;

ANIMALS; CARCINOGENESIS; CARCINOGENS; CELL AGING; ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HUMANS;

EID: 84935091493     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv029     Document Type: Review

References (339)

1. Newbold, R.F. et al. (1982) Induction of immortality is an early event in malignant transformation of mammalian cells by carcinogens. Nature, 299, 633-635.
2. Newbold, R.F. et al. (1983) Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature, 304, 648-651.
3. Hayflick, L. (1965) The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res., 37, 614-636.
4. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
5. Shay, J.W. et al. (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene, 23, 2919-2933.
6. Untergasser, G. et al. (2002) Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res., 62, 6255-6262.
7. Mason, D.X. et al. (2004) Molecular signature of oncogenic ras-induced senescence. Oncogene, 23, 9238-9246.
8. Schwarze, S.R. et al. (2005) The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia, 7, 816-823.
9. Ruiz, L. et al. (2008) Characterization of the p53 response to oncogeneinduced senescence. PLoS One, 3, e3230.
10. Carnero, A. (2013) Markers of cellular senescence. Methods Mol. Biol., 965, 63-81.
11. Lawless, C. et al. (2010) Quantitative assessment of markers for cell senescence. Exp. Gerontol., 45, 772-778.
12. Correia-Melo, C. et al. (2013) Robust multiparametric assessment of cellular senescence. Methods Mol. Biol., 965, 409-419.
13. Narita, M. et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell, 113, 703- 716.
14. Zhang, W. et al. (2008) Comparison of global DNA methylation profiles in replicative versus premature senescence. Life Sci., 83, 475-480.
15. Carnero, A. et al. (2011) Epigenetic mechanisms in senescence, immortalisation and cancer. Biol. Rev. Camb. Philos. Soc., 86, 443-455.
16. d'Adda di Fagagna, F. (2008) Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer, 8. 512-522.
17. d'Adda di Fagagna, F. et al. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature, 426, 194-198.
18. Herbig, U. et al. (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell, 14, 501-513.
19. Passos, J.F. et al. (2012) Mitochondrial dysfunction and cell senescence- skin deep into mammalian aging. Aging (Albany. NY)., 4, 74-75.
20. Olovnikov, A.M. (1973) A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol., 41, 181-190.
21. Wright, W.E. et al. (1995) Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol., 5, 293-297.
22. Kipling, D. et al. (1999) Telomere-dependent senescence. Nat. Biotechnol., 17, 313-314.
23. Collado, M. et al. (2006) The power and the promise of oncogeneinduced senescence markers. Nat. Rev. Cancer, 6, 472-476.
24. Carnero, A. et al.. (2003) Cellular senescence and cancer. Res. Adv. Cancer, 3, 183-198.
25. Chandeck, C. et al. (2010) Oncogene-induced cellular senescence. Adv. Anat. Pathol., 17, 42-48.
26. Braig, M. et al. (2006) Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res., 66, 2881-2884.
27. Courtois-Cox, S. et al. (2008) Many roads lead to oncogene-induced senescence. Oncogene, 27, 2801-2809.
28. Ferrer, I. et al. (2011) Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle, 10, 2751-2762.
29. Alimonti, A. et al. (2010) A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest., 120, 681-693.
30. Bartek, J. et al. (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene, 26, 7773-7779.
31. Ruzankina, Y. et al. (2008) Replicative stress, stem cells and aging. Mech. Ageing Dev., 129, 460-466.
32. Kenyon, J. et al. (2007) The role of DNA damage repair in aging of adult stem cells. Nucleic Acids Res., 35, 7557-7565.
33. Di Micco, R. et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 444, 638-642.
34. Wei, S. et al. (1999) Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res., 59, 1539-1543.
35. Shay, J.W. et al. (2002) Telomerase: a target for cancer therapeutics. Cancer Cell, 2, 257-265.
36. Di Leonardo, A. et al. (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev., 8, 2540-2551.
37. Serrano, M. et al. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88, 593-602.
38. Robles, S.J. et al. (1998) Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene, 16, 1113-1123.
39. Serrano, M. et al. (2001) Putting the stress on senescence. Curr. Opin. Cell Biol., 13, 748-753.
40. Sharpless, N.E. et al. (2004) Telomeres, stem cells, senescence, and cancer. J. Clin. Invest., 113, 160-168.
41. Ben-Porath, I. et al. (2005) The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol., 37, 961-976.
42. Muñoz-Espín, D. et al. (2013) Programmed cell senescence during mammalian embryonic development. Cell, 155, 1104-1118.
43. Storer, M. et al. (2013) Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell, 155, 1119-1130.
44. Counter, C.M. et al. (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. U. S. A., 95, 14723-14728.
45. Hahn, W.C. et al. (1999) Creation of human tumour cells with defined genetic elements. Nature, 400, 464-468.
46. Wang, J. et al. (1998) Myc activates telomerase. Genes Dev., 12, 1769- 1774.
47. Gil, J. et al. (2005) Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res., 65, 2179-2185.
48. Vergel, M. et al. (2010) Bypassing cellular senescence by genetic screening tools. Clin. Transl. Oncol., 12, 410-417.
49. Malumbres, M. et al. (2003) Cell cycle deregulation: a common motif in cancer. Prog. Cell Cycle Res., 5, 5-18.
50. Braig, M. et al. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature, 436, 660-665.
51. Chen, Z. et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 436, 725-730.
52. Michaloglou, C. et al. (2008) BRAF(E600) in benign and malignant human tumours. Oncogene, 27, 877-895.
53. Blanco-Aparicio, C. et al. (2010) Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One, 5, e9305.
54. Russo, I. et al. (1998) A telomere-independent senescence mechanism is the sole barrier to Syrian hamster cell immortalization. Oncogene, 17, 3417-3426.
55. Smith, J.R. et al. (1996) Replicative senescence: implications for in vivo aging and tumor suppression. Science, 273, 63-67.
56. Duncan, E.L. et al. (1993) Assignment of SV40-immortalized cells to more than one complementation group for immortalization. Exp. Cell Res., 205, 337-344.
57. Barrett, J.C. et al. (1994) Cellular senescence and cancer. Cold Spring Harb. Symp. Quant. Biol., 59, 411-418.
58. Feliciano, A. et al. (2011) MicroRNAs regulate key effector pathways of senescence. J. Aging Res., 2011, 205378.
59. Schmitt, C.A. (2007) Cellular senescence and cancer treatment. Biochim. Biophys. Acta, 1775, 5-20.
60. Mooi, W.J. et al. (2006) Oncogene-induced cell senescence-halting on the road to cancer. N. Engl. J. Med., 355, 1037-1046.
61. Carnero, A. et al. (2010) Epigenetic mechanisms in senescence, immortalisation and cancer. Biol. Rev. Camb. Philos. Soc., 86, 443-455..
62. Ferbeyre, G. et al. (2002) Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol., 22, 3497-3508.
63. Demidenko, Z.N. et al. (2008) Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle, 7, 3355-3361.
64. Blagosklonny, M.V. (2010) Calorie restriction: decelerating mTORdriven aging from cells to organisms (including humans). Cell Cycle, 9, 683-688.
65. Castro, M.E. et al. (2008) PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis, 29, 491-499.
66. Narita, M. et al. (2004) Executing cell senescence. Cell Cycle, 3, 244-246.
67. Lin, A.W. et al. (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev., 12, 3008-3019.
68. Lin, A.W. et al. (2001) Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. U. S. A., 98, 5025-5030.
69. Pearson, M. et al. (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature, 406, 207-210.
70. Wynford-Thomas, D. (1996) p53: guardian of cellular senescence. J. Pathol., 180, 118-121.
71. Bond, J. et al. (1996) Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene, 13, 2097-2104.
72. Chin, L. et al. (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell, 97, 527-538.
73. Blaydes, J.P. et al. (1998) The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene, 16, 3317-3322.
74. Kamijo, T. et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell, 91, 649-659.
75. Carnero, A. et al. (2000) p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat. Cell Biol., 2, 148-155.
76. Brown, J.P. et al. (1997) Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science, 277, 831-834.
77. Carnero, A. et al. (2004) Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene, 23, 6006-6011.
78. Pantoja, C. et al. (1999) Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene, 18, 4974-4982.
79. Ho, J.S. et al. (2005) p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell. Biol., 25, 7423-7431.
80. Sherr, C.J. et al. (2002) The RB and p53 pathways in cancer. Cancer Cell, 2, 103-112.
81. Serrano, M. (2003) Proliferation: the cell cycle. Adv. Exp. Med. Biol., 532, 13-17.
82. Classon, M. et al. (2002) The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer, 2, 910-917.
83. Classon, M. et al. (2000) Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc. Natl. Acad. Sci. U. S. A., 97, 10820- 10825.
84. Jarrard, D.F. et al. (1999) p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res., 59, 2957-2964.
85. Haferkamp, S. et al. (2009) The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging (Albany. NY)., 1, 542-556.
86. Ye, X. et al. (2007) Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescenceassociated heterochromatin foci. Mol. Cell. Biol., 27, 2452-2465.
87. Mulligan, G. et al. (1998) The retinoblastoma gene family: cousins with overlapping interests. Trends Genet., 14, 223-229.
88. Burkhart, D.L. et al. (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer, 8, 671-682.
89. Sage, J. et al. (2003) Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature, 424, 223-228.
90. Carnero, A. et al. (1998) The INK4 family of CDK inhibitors. Curr. Top. Microbiol. Immunol., 227, 43-55.
91. Palmero, I. et al. (1997) Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene, 15, 495-503.
92. Gil, J. et al. (2006) Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol., 7, 667-677.
93. Okamoto, A. et al. (1994) p16INK4 mutations and altered expression in human tumors and cell lines. Cold Spring Harb. Symp. Quant. Biol., 59, 49-57.
94. Krimpenfort, P. et al. (2001) Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature, 413, 83-86.
95. Sharpless, N.E. et al. (2001) Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature, 413, 86-91.
96. Yasaei, H. et al. (2013) Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells. Oncogene, 32, 171-179.
97. Jacobs, J.J. et al. (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature, 397, 164-168.
98. Sparmann, A. et al. (2006) Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer, 6, 846-856.
99. Bernard, D. et al. (2005) CBX7 controls the growth of normal and tumorderived prostate cells by repressing the Ink4a/Arf locus. Oncogene, 24, 5543-5551.
100. Alani, R.M. et al. (2001) Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc. Natl. Acad. Sci. U. S. A., 98, 7812-7816.
101. Cummings, S.D. et al. (2008) Id1 delays senescence of primary human melanocytes. Mol. Carcinog., 47, 653-659.
102. Castro, M.E. et al. (2008) PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis, 29, 491-499.
103. Carnero, A. (2010) The PKB/AKT pathway in cancer. Curr. Pharm. Des., 16, 34-44.
104. Blanco-Aparicio, C. et al. (2007) PTEN, more than the AKT pathway. Carcinogenesis, 28, 1379-1386.
105. Lacal, J. et al. (1994) Regulation of ras proteins and their involvement in signal-transduction pathways (review). Oncol. Rep., 1, 677-693.
106. Gottlieb, T.M. et al. (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene, 21, 1299-1303.
107. Sengupta, S. et al. (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell, 40, 310-322.
108. Collado, M. et al. (2000) Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J. Biol. Chem., 275, 21960-21968.
109. Lorenzini, A. et al. (2002) Role of the Raf/MEK/ERK and the PI3K/ Akt(PKB) pathways in fibroblast senescence. Exp. Gerontol., 37, 1149- 1156.
110. Di Cristofano, A. et al. (2001) Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet., 27, 222-224.
111. Trotman, L.C. et al. (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 441, 523-527.
112. Renner, O. et al. (2009) Mouse models to decipher the PI3K signaling network in human cancer. Curr. Mol. Med., 9, 612-625.
113. Renner, O. et al. (2008) Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Res., 68, 9643-9653.
114. Calnan, D.R. et al. (2008) The FoxO code. Oncogene, 27, 2276-2288.
115. Zanella, F. et al. (2010) Understanding FOXO, new views on old transcription factors. Curr. Cancer Drug Targets, 10, 135-146.
116. Greer, E.L. et al. (2008) FOXO transcription factors in ageing and cancer. Acta Physiol. (Oxf)., 192, 19-28.
117. Chen, J. et al. (2006) FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. J. Immunol., 176, 2711-2721.
118. Kyoung Kim, H. et al. (2005) Down-regulation of a forkhead transcription factor, FOXO3a, accelerates cellular senescence in human dermal fibroblasts. J. Gerontol. A. Biol. Sci. Med. Sci., 60, 4-9.
119. Martínez-Gac, L. et al. (2004) Phosphoinositide 3-kinase and Forkhead, a switch for cell division. Biochem. Soc. Trans., 32(Pt 2), 360-361.
120. Wullschleger, S. et al. (2006) TOR signaling in growth and metabolism. Cell, 124, 471-484.
121. Blagosklonny, M.V. (2008) Aging: ROS or TOR. Cell Cycle, 7, 3344-3354.
122. Blagosklonny, M.V. (2009) TOR-driven aging: speeding car without brakes. Cell Cycle, 8, 4055-4059.
123. Anisimov, V.N. et al. (2010) Rapamycin extends maximal lifespan in cancer-prone mice. Am. J. Pathol., 176, 2092-2097.
124. Korotchkina, L.G. et al. (2010) The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany. NY)., 2, 344-352.
125. Young, A.R. et al. (2013) Cell senescence as both a dynamic and a static phenotype. Methods Mol. Biol., 965, 1-13.
126. Singh, K.P. et al. (2008) Allelic loss and mutations in a new ETRG-1 gene are early events in diethylstilbestrol-induced renal carcinogenesis in Syrian hamsters. Gene, 408, 18-26.
127. Tsutsui, T. et al. (1994) Reserpine-induced cell transformation without detectable genetic effects in Syrian hamster embryo cells in culture. Carcinogenesis, 15, 11-14.
128. Martens, U. et al. (1996) Low expression of the WAF1/CIP1 gene product, p21, in enzyme-altered foci induced in rat liver by diethylnitrosamine or phenobarbital. Cancer Lett., 104, 21-26.
129. Newbold, R.F. et al. (1980) Mutagenicity of carcinogenic methylating agents is associated with a specific DNA modification. Nature, 283, 596-599.
130. Brosh, R. et al. (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer, 9, 701-713.
131. Stampfer, M.R. et al. (1985) Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. Proc. Natl. Acad. Sci. U. S. A., 82, 2394- 2398.
132. Lehman, T.A. et al. (1993) p53 mutations in human immortalized epithelial cell lines. Carcinogenesis, 14, 833-839.
133. Dimri, G. et al. (2005) Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res., 7, 171-179.
134. Kang, M.K. et al. (2001) Conversion of normal to malignant phenotype: telomere shortening, telomerase activation, and genomic instability during immortalization of human oral keratinocytes. Crit. Rev. Oral Biol. Med., 12, 38-54.
135. Münger, K. et al. (2002) Human papillomavirus immortalization and transformation functions. Virus Res., 89, 213-228.
136. Trott, D.A. et al. (1995) Mechanisms involved in the immortalization of mammalian cells by ionizing radiation and chemical carcinogens. Carcinogenesis, 16, 193-204.
137. Lafarge-Frayssinet, C. et al. (1989) Over expression of proto-oncogenes: ki-ras, fos and myc in rat liver cells treated in vitro by two liver tumor promoters: phenobarbital and biliverdin. Cancer Lett., 44, 191- 198.
138. Chaumontet, C. et al. (1996) Lack of tumor-promoting effects of flavonoids: studies on rat liver preneoplastic foci and on in vivo and in vitro gap junctional intercellular communication. Nutr. Cancer, 26, 251-263.
139. Rivedal, E. et al. (2000) Morphological transformation and effect on gap junction intercellular communication in Syrian hamster embryo cells as screening tests for carcinogens devoid of mutagenic activity. Toxicol. In Vitro, 14, 185-192.
140. Zhou, X. et al. (2009) Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. Toxicol. Appl. Pharmacol., 236, 78-84.
141. Arita, A. et al. (2009) Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium. Metallomics, 1, 222-228.
142. Creton, S. et al. (2010) Acute toxicity testing of chemicals-opportunities to avoid redundant testing and use alternative approaches. Crit. Rev. Toxicol., 40, 50-83.
143. Bader, A. et al. (2011) Paracetamol treatment increases telomerase activity in rat embryonic liver cells. Pharmacol. Rep., 63, 1435-1441.
144. Tsuruga, Y. et al. (2008) Establishment of immortalized human hepatocytes by introduction of HPV16 E6/E7 and hTERT as cell sources for liver cell-based therapy. Cell Transplant., 17, 1083-1094.
145. Nguyen, T.H. et al. (2005) Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. J. Hepatol., 43, 1031-1037.
146. Bode-Böger, S.M. et al. (2005) Aspirin reduces endothelial cell senescence. Biochem. Biophys. Res. Commun., 334, 1226-1232.
147. Lee, H.R. et al. (2012) Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway. Int. J. Mol. Med., 29, 883-890.
148. Ptak, A. et al. (2011) Effect of bisphenol-A on the expression of selected genes involved in cell cycle and apoptosis in the OVCAR-3 cell line. Toxicol. Lett., 202, 30-35.
149. Tayama, S. et al. (2008) Genotoxic effects of environmental estrogenlike compounds in CHO-K1 cells. Mutat. Res., 649, 114-125.
150. Suzuki, A. et al. (2002) Developmental effects of perinatal exposure to bisphenol-A and diethylstilbestrol on reproductive organs in female mice. Reprod. Toxicol., 16, 107-116.
151. Roy, D. et al. (1997) Biochemical and molecular changes at the cellular level in response to exposure to environmental estrogen-like chemicals. J. Toxicol. Environ. Health, 50, 1-29.
152. Takahashi, A. et al. (2004) Bisphenol A from dental polycarbonate crown upregulates the expression of hTERT. J. Biomed. Mater. Res. B. Appl. Biomater., 71, 214-221.
153. Palmero, I. et al. (1998) p19ARF links the tumour suppressor p53 to Ras. Nature, 395, 125-126.
154. Fauce, S.R. et al. (2008) Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J. Immunol., 181, 7400-7406.
155. Harley, C.B. et al. (2011) A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res., 14, 45-56.
156. Bernardes de Jesus, B. et al. (2011) The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell, 10, 604-621.
157. Jacob, T. et al. (2009) The effect of cotinine on telomerase activity in human vascular smooth muscle cells. J. Cardiovasc. Surg. (Torino)., 50, 345-349.
158. Chau, M.N. et al. (2007) Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3. Carcinogenesis, 28, 2282-2290.
159. Jagadeesh, S. et al. (2006) Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res., 66, 2107-2115.
160. Dong, X.X. et al. (2007) Ginkgo biloba extract reduces endothelial progenitor-cell senescence through augmentation of telomerase activity. J. Cardiovasc. Pharmacol., 49, 111-115.
161. Pearce, V.P. et al. (2008) Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene, 27, 2365-2374.
162. Xia, L. et al. (2008) Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Aktdependent mechanisms. Br. J. Pharmacol., 155, 387-394.
163. Baur, J.A. et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337-342.
164. Artandi, S.E. et al. (2010) Telomeres and telomerase in cancer. Carcinogenesis, 31, 9-18.
165. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
166. Chin, K. et al. (2004) In situ analyses of genome instability in breast cancer. Nat. Genet., 36, 984-988.
167. Raynaud, C.M. et al. (2010) DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. Am. J. Clin. Oncol., 33, 341-345.
168. Sun, L. et al. (2003) Effects of allicin on both telomerase activity and apoptosis in gastric cancer SGC-7901 cells. World J. Gastroenterol., 9, 1930-1934.
169. Ramachandran, C. et al. (2002) Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett., 184, 1-6.
170. Thelen, P. et al. (2004) Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J. Urol., 171, 1934-1938.
171. Meeran, S.M. et al. (2010) Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One, 5, e11457.
172. Naasani, I. (2000) Telomerase inhibitors: forcing the end to put an end. Drug News Perspect., 13, 389-394.
173. Huang, P.R. et al. (2005) Potent inhibition of human telomerase by helenalin. Cancer Lett., 227, 169-174.
174. Mizushina, Y. et al. (2012) Anti-cancer targeting telomerase inhibitors: β-rubromycin and oleic acid. Mini Rev. Med. Chem., 12, 1135-1143.
175. Strahl, C. et al. (1996) Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol., 16, 53-65.
176. Komarov, P.G. et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 285, 1733-1737.
177. Ambs, S. et al. (1999) Cancer-prone oxyradical overload disease. IARC Sci. Publ., 295-302.
178. Borrás, C. et al. (2011) The dual role of p53: DNA protection and antioxidant. Free Radic. Res., 45, 643-652.
179. Holley, A.K. et al. (2012) Manganese superoxide dismutase: beyond life and death. Amino Acids, 42, 139-158.
180. Alfonso, L.F. et al. (2009) Does aspirin acetylate multiple cellular proteins? (Review). Mol. Med. Rep., 2, 533-537.
181. Carmody, R.J. et al. (2001) Signalling apoptosis: a radical approach. Redox Rep., 6, 77-90.
182. Maehle, L. et al. (1992) Altered p53 gene structure and expression in human epithelial cells after exposure to nickel. Cancer Res., 52, 218- 221.
183. Flora, S.J. (2011) Arsenic-induced oxidative stress and its reversibility. Free Radic. Biol. Med., 51, 257-281.
184. De Chaudhuri, S. et al. (2008) Arsenic-induced health effects and genetic damage in keratotic individuals: involvement of p53 arginine variant and chromosomal aberrations in arsenic susceptibility. Mutat. Res., 659, 118-125.
185. Shi, H. et al. (2004) Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol. Cell. Biochem., 255, 67-78.
186. Kitchin, K.T. (2001) Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol., 172, 249-261.
187. Brüne, B. et al. (2001) Transcription factors p53 and HIF-1alpha as targets of nitric oxide. Cell. Signal., 13, 525-533.
188. Ekmekcioglu, S. et al. (2005) NO news is not necessarily good news in cancer. Curr. Cancer Drug Targets, 5, 103-115.
189. Brown, G.C. (2010) Nitric oxide and neuronal death. Nitric Oxide, 23, 153-165.
190. Davis, C.D. et al. (2000) Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J. Nutr., 130, 2903-2909.
191. Arnér, E.S. et al. (2006) The thioredoxin system in cancer. Semin. Cancer Biol., 16, 420-426.
192. Howitz, K.T. et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425, 191-196.
193. Malhotra, A. et al. (2012) Curcumin and resveratrol in combination modulates benzo(a)pyrene-induced genotoxicity during lung carcinogenesis. Hum. Exp. Toxicol., 31, 1199-1206.
194. Alcaín, F.J. et al. (2009) Sirtuin activators. Expert Opin. Ther. Pat., 19, 403-414.
195. Athar, M. et al. (2009) Multiple molecular targets of resveratrol: anticarcinogenic mechanisms. Arch. Biochem. Biophys., 486, 95-102.
196. Duntas, L.H. (2011) Resveratrol and its impact on aging and thyroid function. J. Endocrinol. Invest., 34, 788-792.
197. Harikumar, K.B. et al. (2008) Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle, 7, 1020-1035.
198. Maclaine, N.J. et al. (2009) The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany. NY)., 1, 490-502.
199. Blasina, A. et al. (1999) Caffeine inhibits the checkpoint kinase ATM. Curr. Biol., 9, 1135-1138.
200. Tichy, E.D. (2011) Mechanisms maintaining genomic integrity in embryonic stem cells and induced pluripotent stem cells. Exp. Biol. Med. (Maywood)., 236, 987-996.
201. Dhillon, S. (2013) Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs, 73, 475-485.
202. Chavez-MacGregor, M. et al. (2012) Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin. Investig. Drugs, 21, 1835-1843.
203. Kruck, S. et al. (2012) Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev. Anticancer Ther., 12, 777- 785.
204. Barnett, C.M. (2012) Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Pharmacotherapy, 32, 383-396.
205. Zhang, J. et al. (2012) The role of α-synuclein and tau hyperphosphorylation-mediated autophagy and apoptosis in lead-induced learning and memory injury. Int. J. Biol. Sci., 8, 935-944.
206. Ma, J.S. et al. (2010) Gold nanoparticles attenuate LPS-induced NO production through the inhibition of NF-kappaB and IFN-beta/STAT1 pathways in RAW264.7 cells. Nitric Oxide, 23, 214-219.
207. Wang, B. et al. (2012) Akt signaling-associated metabolic effects of dietary gold nanoparticles in Drosophila. Sci. Rep., 2, 563.
208. Jang, S. et al. (2012) Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation. Int. J. Nanomed., 7, 1329-1343.
209. Kalishwaralal, K. et al. (2009) Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells. Colloids Surf. B. Biointerfaces, 73, 51-57.
210. Piao, M.J. et al. (2011) Silver nanoparticles down-regulate Nrf2-mediated 8-oxoguanine DNA glycosylase 1 through inactivation of extracellular regulated kinase and protein kinase B in human Chang liver cells. Toxicol. Lett., 207, 143-148.
211. Piao, M.J. et al. (2011) Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis. Toxicol. Lett., 201, 92-100.
212. Huang, J. et al. (2011) Cancer chemoprevention by targeting the epigenome. Curr. Drug Targets, 12, 1925-1956.
213. Li, Y. et al. (2009) Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int. J. Cancer, 125, 286-296.
214. Harman, D. (1956) Aging: a theory based on free radical and radiation chemistry. J. Gerontol., 11, 298-300.
215. Campisi, J. (2011) Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev., 21, 107-112.
216. Vergel, M. et al. (2010) Cellular senescence as a target in cancer control. J. Aging Res., 2011, 725365.
217. Lleonart, M.E. et al. (2009) Senescence induction; a possible cancer therapy. Mol. Cancer, 8, 3.
218. Hosokawa, M. (2002) A higher oxidative status accelerates senescence and aggravates age-dependent disorders in SAMP strains of mice. Mech. Ageing Dev., 123, 1553-1561.
219. Itahana, K. et al. (2004) Mechanisms of cellular senescence in human and mouse cells. Biogerontology, 5, 1-10.
220. Serrano, M. et al. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88, 593-602.
221. Itahana, K. et al. (2003) Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol. Cell. Biol., 23, 389-401.
222. Serra, V. et al. (2003) Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening. J. Biol. Chem., 278, 6824-6830.
223. Parkes, T.L. et al. (1998) Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat. Genet., 19, 171- 174.
224. Orr, W.C. et al. (1994) Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. Science, 263, 1128-1130.
225. Lee, A.C. et al. (1999) Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem., 274, 7936-7940.
226. Woo, H.R. et al. (2004) The delayed leaf senescence mutants of Arabidopsis, ore1, ore3, and ore9 are tolerant to oxidative stress. Plant Cell Physiol., 45, 923-932.
227. Larsen, P.L. et al. (2002) Extension of life-span in Caenorhabditis elegans by a diet lacking coenzyme Q. Science, 295, 120-123.
228. Palmer, M.R. et al. (2003) The effects of dietary coenzyme Q on Drosophila life span. Aging Cell, 2, 335-339.
229. Toyokuni, S. (1996) Iron-induced carcinogenesis: the role of redox regulation. Free Radic. Biol. Med., 20, 553-566.
230. Fukuda, A. et al. (1996) Oxidative stress response in iron-induced renal carcinogenesis: acute nephrotoxicity mediates the enhanced expression of glutathione S-transferase Yp isozyme. Arch. Biochem. Biophys., 329, 39-46.
231. Tanaka, T. et al. (1999) High incidence of allelic loss on chromosome 5 and inactivation of p15INK4B and p16INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene, 18, 3793-3797.
232. Kondoh, H. et al. (2005) Glycolytic enzymes can modulate cellular life span. Cancer Res., 65, 177-185.
233. Kondoh, H. et al. (2007) Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization. Histol. Histopathol., 22, 85-90.
234. Hitosugi, T. et al. (2012) Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell, 22, 585-600.
235. Kaplon, J. et al. (2013) A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature, 498, 109-112.
236. Dörr, J.R. et al. (2013) Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature, 501, 421-425.
237. Virchow, R. (1858) Reizung and Reizbarkeit. Arch. Pathol. Anat. Klin. Med., 14, 1-63.
238. Virchow, R. (1863) Aetiologie der neoplastischen Geshwültse/Pathogenie der neoplastishchen Geshwülste. Die Krankhaften Geschwülste, 57-101.
239. Colotta, F. et al. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-1081.
240. Balkwill, F. et al. (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7, 211-217.
241. van der Woude, C.J. et al. (2004) Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis, 9, 123-130.
242. Oshima, M. et al. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
243. Guerra, C. et al. (2011) Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell, 19, 728-739.
244. Philip, M. et al. (2004) Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol., 14, 433-439.
245. Guerra, C. et al. (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell, 11, 291-302.
246. Carrière, C. et al. (2011) Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology, 141, 1091-1101.
247. Narlik-Grassow, M. et al. (2014) Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. PLoS One, 8, e60277.
248. Xue, W. et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445, 656-660.
249. Hudson, J.D. et al. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med., 190, 1375-1382.
250. Acosta, J.C. et al. (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell, 133, 1006-1018.
251. Coppé, J.P. et al. (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol., 5, 99- 118.
252. Coppé, J.P. et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol., 6, 2853-2868.
253. Krtolica, A. et al. (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U. S. A., 98, 12072-12077.
254. Liu, D. et al. (2007) Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res., 67, 3117-3126.
255. Acosta, J.C. et al. (2013) A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol., 15, 978-990.
256. Olivieri, F. et al. (2012) Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging. Mech. Ageing Dev., 133, 675-685.
257. Labbaye, C. et al. (2012) The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J. Hematol. Oncol., 5, 13.
258. Chen, Q.M. (2000) Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann. N. Y. Acad. Sci., 908, 111-125.
259. Chang, B.D. et al. (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res., 59, 3761-3767.
260. Wang, X. et al. (1998) Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res., 58, 5019-5022.
261. Yeo, E.J. et al. (2000) Senescence-like changes induced by hydroxyurea in human diploid fibroblasts. Exp. Gerontol., 35, 553-571.
262. Michishita, E. et al. (1999) 5-Bromodeoxyuridine induces senescencelike phenomena in mammalian cells regardless of cell type or species. J. Biochem., 126, 1052-1059.
263. Chang, B.D. et al. (1999) Role of p53 and p21waf1/cip1 in senescencelike terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene, 18, 4808-4818.
264. Elmore, L.W. et al. (2002) Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem., 277, 35509-35515.
265. Belgiovine, C. et al. (2008) Telomerase: cellular immortalization and neoplastic transformation. Multiple functions of a multifaceted complex. Cytogenet. Genome Res., 122, 255-262.
266. Low, K.C. et al. (2013) Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem. Sci., 38, 426-434.
267. Xi, L. et al. (2006) Inhibition of telomerase enhances apoptosis induced by sodium butyrate via mitochondrial pathway. Apoptosis, 11, 789-798.
268. Hashimoto, Y. et al. (2012) The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment. PLoS ONE, 7, e39292.
269. Liu, J. et al. (2013) Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett.
270. Puzio-Kuter, A.M. et al. (2009) Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev., 23, 675-680.
271. Ravi, R. et al. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev., 14, 34-44.
272. Hanel, W. et al. (2012) Links between mutant p53 and genomic instability. J. Cell. Biochem., 113, 433-439.
273. Chipuk, J.E. et al. (2006) Dissecting p53-dependent apoptosis. Cell Death Differ., 13, 994-1002.
274. Niebler, M. et al. (2013) Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog., 9, e1003536.
275. Lee, J.S. et al. (2013) A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. Neuro Oncol., 16, 191-203.
276. Goh, A.M. et al. (2011) The role of mutant p53 in human cancer. J. Pathol., 223, 116-126.
277. Gudkov, A.V. et al. (2011) Inflammation and p53: a tale of two stresses. Genes Cancer, 2, 503-516.
278. Lorin, S. et al. (2013) Autophagy regulation and its role in cancer. Semin. Cancer Biol., 23, 361-379.
279. Nicolay, B.N. et al. (2013) Loss of RBF1 changes glutamine catabolism. Genes Dev., 27, 182-196.
280. Di Fiore, R. et al. (2013) RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J. Cell. Physiol., 228, 1676-1687.
281. Gabellini, C. et al. (2006) Involvement of RB gene family in tumor angiogenesis. Oncogene, 25, 5326-5332.
282. Amato, A. et al. (2009) CENPA overexpression promotes genome instability in pRb-depleted human cells. Mol. Cancer, 8, 119.
283. Attardi, L.D. et al. (2013) RB goes mitochondrial. Genes Dev., 27, 975- 979.
284. Gore, A.J. et al. (2014) Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. J. Clin. Invest., 124, 338-352.
285. Chou, N.H. et al. (2006) Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma. World J. Gastroenterol., 12, 7188-7191.
286. Ying, L. et al. (2007) Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res., 67, 9286-9293.
287. Mankame, T.P. et al. (2012) The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7. Neoplasia, 14, 1213-1222.
288. Corominas-Faja, B. et al. (2013) Nuclear reprogramming of luminallike breast cancer cells generates Sox2-overexpressing cancer stemlike cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle, 12, 3109-3124.
289. Zhou, W. et al. (2013) Dysregulation of mTOR activity through LKB1 inactivation. Chin. J. Cancer, 32, 427-433.
290. Kong, D. et al. (2008) Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in plateletderived growth factor-D-overexpressing PC3 cells. Cancer Res., 68, 1927-1934.
291. Guo, F. et al. (2013) mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells. Leukemia, 27, 2040-2046.
292. Shi, Y. et al. (1995) Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res., 55, 1982-1988.
293. Heavey, S. et al. (2014) Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev., 40, 445-456.
294. Zhou, H. et al. (2011) Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr. Protein Pept. Sci., 12, 30-42.
295. Lee, D.F. et al. (2007) All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle, 6, 3011-3014.
296. Fraisl, P. (2013) Crosstalk between oxygen- and nitric oxide-dependent signaling pathways in angiogenesis. Exp. Cell Res., 319, 1331- 1339.
297. Ziche, M. et al. (2009) Molecular regulation of tumour angiogenesis by nitric oxide. Eur. Cytokine Netw., 20, 164-170.
298. Wu, Y. et al. (2014) Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett., 345, 164-173.
299. Avezum, A. et al. (2005) Risk factors associated with acute myocardial infarction in the São Paulo metropolitan region: a developed region in a developing country. Arq. Bras. Cardiol., 84, 206-213.
300. Hickok, J.R. et al. (2010) Nitric oxide and cancer therapy: the emperor has NO clothes. Curr. Pharm. Des., 16, 381-391.
301. Altinoz, M.A. et al. (2004) NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma, 51, 239-247.
302. Kon, K. et al. (2007) Role of apoptosis in acetaminophen hepatotoxicity. J. Gastroenterol. Hepatol., 22 (suppl. 1), S49-S52.
303. Singh, Y. et al. (2013) Selective poisoning of Ctnnb1-mutated hepatoma cells in mouse liver tumors by a single application of acetaminophen. Arch. Toxicol., 87, 1595-1607.
304. Scheiermann, P. et al. (2013) Application of interleukin-22 mediates protection in experimental acetaminophen-induced acute liver injury. Am. J. Pathol., 182, 1107-1113.
305. Ucar, F. et al. (2013) The effects of N-acetylcysteine and ozone therapy on oxidative stress and inflammation in acetaminophen-induced nephrotoxicity model. Ren. Fail., 35, 640-647.
306. Ryu, Y.S. et al. (2000) Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. Biochem. Biophys. Res. Commun., 272, 758-764.
307. Conklin, B.S. et al. (2002) Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am. J. Pathol., 160, 413-418.
308. Nakada, T. et al. (2012) Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. J. Toxicol. Sci., 37, 555-563.
309. Rehani, K. et al. (2008) Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim. Biophys. Acta, 1783, 375-382.
310. Radisavljevic, Z. (2004) Inactivated tumor suppressor Rb by nitric oxide promotes mitosis in human breast cancer cells. J. Cell. Biochem., 92, 1-5.
311. Wang, X. et al. (2003) Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation. Cell Death Differ., 10, 468-476.
312. Brüne, B. (2003) Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ., 10, 864-869.
313. Rahat, M.A. et al. (2013) Macrophage-tumor cell interactions regulate the function of nitric oxide. Front. Physiol., 4, 144.
314. Ishida, A. et al. (1999) Tumor suppressor p53 but not cGMP mediates NO-induced expression of p21(Waf1/Cip1/Sdi1) in vascular smooth muscle cells. Mol. Pharmacol., 56, 938-946.
315. Williams, E.L. et al. (2005) Nitric oxide and metastatic cell behaviour. Bioessays, 27, 1228-1238.
316. Través, P.G. et al. (2012) Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm., 2012, 568783.
317. Jiang, C. et al. (1999) Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol. Carcinog., 26, 213-225.
318. Sarveswaran, S. et al. (2010) Selenite triggers rapid transcriptional activation of p53, and p53-mediated apoptosis in prostate cancer cells: implication for the treatment of early-stage prostate cancer. Int. J. Oncol., 36, 1419-1428.
319. Li, Z. et al. (2013) Sodium selenite induces apoptosis in colon cancer cells via Bax-dependent mitochondrial pathway. Eur. Rev. Med. Pharmacol. Sci., 17, 2166-2171.
320. Jiang, Q. et al. (2013) ATF4 activation by the p38MAPK-eIF4E axis mediates apoptosis and autophagy induced by selenite in Jurkat cells. FEBS Lett., 587, 2420-2429.
321. Yoon, S.O. et al. (2001) Inhibitory effect of selenite on invasion of HT1080 tumor cells. J. Biol. Chem., 276, 20085-20092.
322. Rusolo, F. et al. (2013) Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines. Molecules, 18, 2549- 2562.
323. Dulhunty, A.F. (1992) The voltage-activation of contraction in skeletal muscle. Prog. Biophys. Mol. Biol., 57, 181-223.
324. Pan, J.J. et al. (2011) Activation of Akt/GSK3β and Akt/Bcl-2 signaling pathways in nickel-transformed BEAS-2B cells. Int. J. Oncol., 39, 1285- 1294.
325. Namiki, A. et al. (1995) Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J. Biol. Chem., 270, 31189- 31195.
326. Coen, N. et al. (2001) Heavy metals of relevance to human health induce genomic instability. J. Pathol., 195, 293-299.
327. Chen, C.Y. et al. (2010) Nickel(II)-induced oxidative stress, apoptosis, G2/M arrest, and genotoxicity in normal rat kidney cells. J. Toxicol. Environ. Health. A, 73, 529-539.
328. Yang, Y.X. et al. (2013) Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells. Int. J. Oncol., 43, 936-946.
329. D'Antò, V. et al. (2012) Effect of nickel chloride on cell proliferation. Open Dent. J., 6, 177-181.
330. Ding, J. et al. (2009) Effects of nickel on cyclin expression, cell cycle progression and cell proliferation in human pulmonary cells. Cancer Epidemiol. Biomarkers Prev., 18, 1720-1729.
331. Sainte-Marie, I. et al. (1998) Comparative study of the in vitro inflammatory activity of three nickel salts on keratinocytes. Acta Derm. Venereol., 78, 169-172.
332. Wu, C.H. et al. (2012) Nickel-induced epithelial-mesenchymal transition by reactive oxygen species generation and E-cadherin promoter hypermethylation. J. Biol. Chem., 287, 25292-25302.
333. Fracasso, M.E. et al. (2002) Lead induced DNA strand breaks in lymphocytes of exposed workers: role of reactive oxygen species and protein kinase C. Mutat. Res., 515, 159-169.
334. Ma, Y. et al. (2012) Effect of lead on apoptosis in cultured rat primary osteoblasts. Toxicol. Ind. Health, 28, 136-146.
335. Tchounwou, P.B. et al. (2004) Lead-induced cytotoxicity and transcriptional activation of stress genes in human liver carcinoma (HepG2) cells. Mol. Cell. Biochem., 255, 161-170.
336. Liu, C.M. et al. (2012) Protective role of quercetin against lead-induced inflammatory response in rat kidney through the ROS-mediated MAPKs and NF-κB pathway. Biochim. Biophys. Acta, 1820, 1693-1703.
337. Bagaitkar, J. et al. (2012) Cotinine inhibits the pro-inflammatory response initiated by multiple cell surface Toll-like receptors in monocytic THP cells. Tob. Induc. Dis., 10, 18.
338. Brozmanová, J. et al. (2010) Selenium: a double-edged sword for defense and offence in cancer. Arch. Toxicol., 84, 919-938.
339. Erkhembayar, S. et al. (2012) The effect of sodium selenite on liver growth and thioredoxin reductase expression in regenerative and neoplastic liver cell proliferation. Biochem. Pharmacol., 83, 687-693.